Jurox (UK) Limited has enhanced its comprehensive anaesthesia and analgesia portfolio with the reformulation of Buprelieve to contain the well-known preservative, benzethonium chloride.
Buprelieve will be the first buprenorphine multidose preparation to contain benzethonium chloride, a change which sees reduced pain on injection when compared to buprenorphine multidose formulations that are preserved with chlorocresol 1.35mg/ml.
Benzethonium chloride is a tried and tested veterinary pharmaceutical preservative, which is present in licensed veterinary formulations of butorphanol and ketamine at the same concentration of 0.1mg/ml. It is also present in Jurox’s popular Alfaxan Multidose at 0.2mg/ml.
Buprelieve’s reformulation will help reduce waste associated with unpreserved ampule formulations and will help streamline portfolios with a requirement for only one buprenorphine listing.
Dan Cripwell, BSc (Hons), BVSc, CertAVP (EM), CertAVP, PgCert (VPS), MRCVS, advanced veterinary practitioner and senior veterinary technical advisor at Jurox (UK) Limited, comments: “I am delighted that Jurox can provide the UK veterinary market with this evolution of our multidose buprenorphine formulation. We constantly strive to provide the veterinary profession with first class clinical and technical support and our ability to perform in-house product research and development is also a great strength; this allows us to remain agile enough to make adaptations in an area where not much has changed in the past few years.
“In this instance, we were able to examine what improvements could be made to our existing drug portfolio and respond to the profession’s feedback with the redevelopment of the commonly utilised opioid analgesic, buprenorphine. Our hope is that, as well as the recent mixing claims added to the product licence, this development will encourage the best clinical use of the drug and, in turn, improve patient experience and outcome.”
Buprelieve is a cost-effective opioid analgesic licensed for use in dogs, cats and horses. It provides post-operative analgesia in all three species and potentiates the sedative effects of other centrally-acting agents in dogs and horses. It can be administered by intramuscular or intravenous injection to dogs and cats and by intravenous injection to horses. It is available in a 10ml multi-dose glass vial for easy administration. Due to the light sensitivity of Buprelieve, it will still be packaged in an amber vial. There is no bung broach limit within the 28-day shelf-life following initial broach and Buprelieve is the only buprenorphine formulation that can be combined in the same syringe as either acepromazine or medetomidine/dexmedetomidine on licence.
For further information on Jurox’s extensive range of anaesthesia and analgesia products, please contact your local Jurox account manager by phoning 0800 500 3171, visit the Jurox website or email email@example.com.